Featured Research

from universities, journals, and other organizations

ACL reconstructions may last longer with autografts

Date:
July 11, 2014
Source:
American Orthopaedic Society for Sports Medicine (AOSSM)
Summary:
Anterior Cruciate Ligament (ACL) reconstructions occur more than 200,000 times a year, but the type of material used to create a new ligament may determine how long you stay in the game, say researchers.

Anterior Cruciate Ligament (ACL) reconstructions occur more than 200,000 times a year, but the type of material used to create a new ligament may determine how long you stay in the game, say researchers presenting their work today at the Annual Meeting of the American Orthopaedic Society of Sports Medicine (AOSSM).

"Our study results highlight that in a young athletic population, allografts (tissue harvested from a donor) fail more frequently than using autografts (tissue harvested from the patient)," said Craig R. Bottoni, MD, lead author from Tripler Army Medical Center in Honolulu, Hawaii. "After following the patients for 10 years, more than 80 percent of all grafts were intact and had maintained stability. However, those patients who had an allograft, failed at a rate more than three times higher than those reconstructed with an autograft. This study was also of only one type of allograft (Tibialis Posterior). Therefore, we can make a strong statement about that type and not necessarily extrapolate to other types of allografts, most notably those with bone, i.e. BTB or Achilles."

Bottoni and his team, followed 99 patients who had used either an autograft or allograft for their ACL reconstruction. All allografts were from a single tissue bank, aseptically processed and fresh frozen without terminal irradiation. Graft fixation was identical in all knees. All patients followed the same post-operative rehabilitation protocol. The primary outcome measures were graft integrity, subjective knee stability and functional status.

Eighty-seven of the patients were male with 95 individuals in active duty military. Both groups were similar in demographics and preoperative activity level. The mean and median age of both groups was identical at 29 and 26, respectively. There were four (8.3%) autograft and 13 (26.5%) allograft failures which required revision reconstruction. In the remaining patients whose graft was intact, there was no difference in the mean SANE, Tegner, or IKDC scores.

"By better understanding why and how grafts fail in ACL reconstructions, we can increase the life span of these procedures and minimize future surgeries where feasible," said Bottoni.


Story Source:

The above story is based on materials provided by American Orthopaedic Society for Sports Medicine (AOSSM). Note: Materials may be edited for content and length.


Cite This Page:

American Orthopaedic Society for Sports Medicine (AOSSM). "ACL reconstructions may last longer with autografts." ScienceDaily. ScienceDaily, 11 July 2014. <www.sciencedaily.com/releases/2014/07/140711091818.htm>.
American Orthopaedic Society for Sports Medicine (AOSSM). (2014, July 11). ACL reconstructions may last longer with autografts. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/07/140711091818.htm
American Orthopaedic Society for Sports Medicine (AOSSM). "ACL reconstructions may last longer with autografts." ScienceDaily. www.sciencedaily.com/releases/2014/07/140711091818.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins